Mene Pangalos, AstraZeneca R&D chief (AstraZeneca via YouTube)
October 2, 2020 09:18 AM EDT
R&D
FDA+

The FDA hands Farx­i­ga 'break­through' sta­tus in CKD, clear­ing path for As­traZeneca's much-tout­ed ther­a­py

Jason Mast

Editor

As­traZeneca has been promis­ing big things on Farx­i­ga in kid­ney dis­ease since March, when they stopped a Phase III tri­al over what they deemed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times